SRC and breast carcinoma: Diosgenin showed stable non-bonded interactions forming stable binary complexes with all three screened targets namely SRC, MDM2, and IGF1R. Thus, we proposed that these stable interactions of Diosgenin would trigger the successful inhibition of SRC, MDM2, and IGF1R; the newly identified targets in breast cancer.